Join the Ozempic group to help and get support from people like you.
Ozempic News (Page 5)
Ozempic, Wegovy Linked To Potential Vision Loss
MONDAY, Feb. 24, 2025 – People taking the weight-loss drug semaglutide could be at a slightly increased risk for a potentially blinding eye condition that affects the optic nerve, a new study says....
Certain Glucose-Lowering Meds Associated With Lower Risk for COPD Exacerbations
FRIDAY, Feb. 21, 2025 – For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1...
Senators Call on FDA to Act Against Misleading Weight-Loss Drug Commercials
WEDNESDAY, Feb. 12, 2025 – Commercials run by the telehealth company Hims & Hers have been placed under the microscope as lawmakers are calling out advertisement of prescription of injectable...
More Evidence Ozempic Can Curb Alcoholism
WEDNESDAY, Feb. 12, 2025 – Yet another study is supporting the notion that the blockbuster GLP-1 drug Ozempic can help problems drinkers curb their intake. The research found that, compared to...
GLP-1 Meds Can Work Wonders for Kidney Health
TUESDAY, Feb. 11, 2025 – Ozempic, Wegovy, Saxenda, Trulicity: These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new research shows....
Can GLP-1 Meds Harm Your Eyes?
MONDAY, Feb. 10, 2025 – Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight loss drugs, but the jury's out on whether the medications caused the eye trouble, according...
New Facial Plastic Surgery Survey Illustrates Impact of GLP-1 Receptor Agonists
FRIDAY, Feb. 7, 2025 – Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the field of facial plastic surgery, according to the results of...
'Ozempic Face' and Other Top Trends in Plastic Surgery
FRIDAY, Feb. 7, 2025 – Add surgical tweaks to fix so-called "Ozempic face" to the list of top trending cosmetic procedures, as tallied by the American Academy of Facial Plastic and Reconstructive...
Prescriptions for Obesity Management Drugs Increasing
THURSDAY, Feb. 6, 2025 – Prescriptions of obesity management drugs (OMDs) have increased, and these increasing trends are associated with online search trends, according to a study published online...
Ozempic-Type Drug Fails To Slow Parkinson’s, Study Finds
WEDNESDAY, Feb. 5, 2025 – Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's disease have taken an hit. A new study found that a drug in the same class called exenatide,...
FDA OK's Ozempic To Protect Kidneys in Type 2 Diabetes Patients
WEDNESDAY, Jan. 29, 2025 – A popular diabetes drug just got a major new approval – and it could be a game-changer for millions of Americans at risk for kidney failure. The U.S. Food and Drug...
FDA Approves Ozempic (semaglutide) as the Only GLP-1 RA to Reduce the Risk of Worsening Kidney Disease and Cardiovascular Death in Adults with Type 2 Diabetes and Chronic Kidney Disease
PLAINSBORO, N.J., Jan. 28, 2025 /PRNewswire/ – Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved Ozempic to reduce the risk of kidney disease worsening,...
Several Factors Play Role in Semaglutide Initiation for Obesity Without Diabetes
THURSDAY, Jan. 23, 2025 – Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but without diabetes, according to a study published...
Websites Selling Compounded GLP-1 RAs Often Misinform Consumers
TUESDAY, Jan. 21, 2025 – Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers, including with respect to U.S. Food and...
No Link Seen Between GLP-1 Receptor Agonist Use and Thyroid Cancer
WEDNESDAY, Jan. 22, 2025 – Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published ...
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Chronic Kidney Disease, Cardiovascular Risk Reduction, Diabetes, Type 2